thymosin and Coronary-Stenosis

Thymosin β4 was recently demonstrated to be a potential stimulator of angiogenesis and arteriogenesis in both in-vivo and in-vitro studies. Little is known about the relationship between serum thymosin β4 levels and the extent of coronary collaterals in patients with coronary artery disease.. Serum thymosin β4 independently predicts the formation of coronary collaterals in patients with coronary artery disease.. A total of 190 consecutive patients who underwent coronary angiography were divided into two groups according to coronary angiograms and collateral formation: the poor collateral group consisting of 103 patients with at least more than or equal to one coronary stenosis of greater than or equal to 75% without visible collateral circulation, and the good collateral group consisting of 87 patients with at least more than or equal to one coronary stenosis of greater than or equal to 75% with well-developed collateral circulation. Collateral score was analyzed using the Cohen-Rentrop classification.. Serum thymosin β4 levels were 1024.50 ± 516.92 ng/ml and 1373.00 ± 1082.88 ng/ml for patients in the poor collateral group and the good collateral group, respectively. Serum thymosin β4 levels in the good collateral group were significantly higher than those in the poor collateral group (P<0.01). After adjustment in the multiple ordinal logistic regression model, serum thymosin β4 levels showed a strong independent association with the collateral Cohen-Rentrop score (χ(2)=4.45, odds ratio=1.00, 95% confidence interval: 1.000-1.002, P=0.035).. Elevated serum thymosin β4 level is independently associated with a significant enhancement in coronary collateralization and patients in the good collateral tend to have a higher thymosin β4 level.

Topics: Aged; Biomarkers; Chi-Square Distribution; China; Collateral Circulation; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Severity of Illness Index; Thymosin; Up-Regulation

Thymosin beta 4 (Tβ4) plays an essential role in cardiac vessel development and is currently being developed as a therapeutic agent for the treatment of coronary artery disease (CAD) in some experimental studies. Thus, we aimed to investigate the association of serum Tβ4 levels and collateral formation in patients presenting with severely stenotic CAD.. Thirteen patients with poor collateral development and 16 age- and sex-matched patients with good collateral development who had ≥ 95% stenosis in at least one major coronary artery on coronary angiogram (CAG) were enrolled in the study. The Gensini score was calculated for each patient by using CAG results. Collateral development was classified according to the Cohen-Rentrop method. Serum Tβ4 levels were measured with enzyme-linked immune sorbent assay.. There were no statistically significant differences between the two groups in regard to clinical and laboratory characteristics of the patients except for Tβ4 levels. The Tβ4 levels in the well-collateralized study group were found to be significantly higher than those of the poorly collateralized study group and serum Tβ4 levels were positively correlated with the collateral development.. Our findings suggest that serum Tβ4 levels are significantly associated with the collateral development in severe CAD.

Topics: Aged; Biomarkers; Case-Control Studies; Collateral Circulation; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Research Design; Thymosin; Turkey